BioSpace News Archive

Drug Development

Ionis and Roche Tout Positive Data in Early-Stage Huntington’s Disease Trial

Late Thursday the companies touted biomarker data from an early-stage study that showed the drug lowered the disease-causing protein in people with the disease.

March 2, 2018
·
2 min read
·
Alex Keown
FDA

FDA Issues New Draft Guidance for Alzheimer’s Trials that Could Open Up Approvals

The U.S. Food and Drug Administration (FDA) issued new draft guidance for preclinical trials in Alzheimer’s.

March 2, 2018
·
3 min read
·
Mark Terry
Drug Development

Sanofi and Regeneron Seek FDA Approval of Dupixent as Add-On Asthma Therapy

Asthma patients may soon have a new treatment option.

March 2, 2018
·
2 min read
·
Alex Keown
Drug Development

MeiraGTx Earns EMA PRIME Designation for Achromatopsia Gene Therapy Candidate

A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe.

March 2, 2018
·
2 min read
·
Alex Keown
Business

OPKO Health’s Annual Report a Mixed Bag

OPKO Health’s fourth-quarter report highlighted positive activities in the face of a net loss of $213.9 million during the most recent quarter.

March 2, 2018
·
3 min read
·
Mark Terry
BioMidwest

Biogen and AbbVie Voluntarily Pull Multiple Sclerosis Drug Off the Market

Biogen and AbbVie have voluntarily pulled their Zinbryta for relapsing multiple sclerosis (MS) off the market after safety concerns.

March 2, 2018
·
2 min read
·
Mark Terry
Career Advice

Say “No” the Right Way: How Declining a Job Offer can Advance Your Career

Figuring out the best way to turn down a job offer is a “good” problem to have. If anything, receiving one or multiple job offers gives you a sense of your professional currency on the job market and could even make you a more attractive candidate for other potential employers.

March 2, 2018
·
4 min read
Genetown

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

Biogen and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis. The companies believe that characterizing the complex and evolving benefit/risk profile of ZINBRYTA will not be possible going forward given the limited number of patients being treated.

March 2, 2018
·
2 min read
Business

Revolutionary Robotic Treatment For Patients With Spinal Cord Injuries Now Available In United States

New advanced technology available at Brooks Rehabilitation, in partnership with Japan-based Cyberdyne, Inc.

March 2, 2018
·
4 min read
Biotech Beach

Glaukos Announces Participation in 30th Annual ROTH Conference

Glaukos is ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma

March 2, 2018
·
1 min read